Novo Nordisk’s ziltivekimab failed to reduce cardiovascular events in a Phase 3 trial, dealing a blow to a drug once forecast to generate about $3 billion in peak annual sales.
The post ZEUS failure clouds future...
Subscribe to European Biotechnology Magazine’s news feed.
Click on “Follow” and decide if you want to get news from European Biotechnology Magazine via RSS, as email newsletter, via mobile or on your personal news page.
Subscription to European Biotechnology Magazine comes without risk as you can unsubscribe instantly at any time.
You can also filter the feed to your needs via topics and keywords so that you only receive the news from European Biotechnology Magazine which you are really interested in. Click on the blue “Filter” button below to get started.
Website title: European Biotechnology Magazine